Endpoints News 29. Jan. 2026 Sanofi says its €15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliff
Endpoints News 28. Jan. 2026 Round three of IRA negotiations is expected to be ‘manageable’ for pharma
Endpoints News 28. Jan. 2026 Lonza still intends to sell its capsules and health ingredients business
Endpoints News 28. Jan. 2026 FDA suspends Regenxbio gene therapy trials after patient developed brain tumor